FDA greenlights Ziosoft MR cardiac function analysis app
Ziosoft, a developer of advanced visualization and analysis software for medical imaging, has received 510(k) clearance from the FDA to market its MR cardiac function analysis application for use with the Ziostation thin-client system.
The MR cardiac function analysis application is used by physicians to evaluate the structures and function of the heart in the initial screening and subsequent management of coronary disease patients, according to the Redwood City, Calif.-based company.
Ziosoft said its MR cardiac function application provides physicians with the capability to extract left ventricle myocardial contours from Ziosoft's interpolation algorithm. In addition to functional assessment calculations such as ejection fraction, peak filling rate and peak ejection rate, the automatic calculation of myocardial mass also is generated with the Ziosoft application, according to the firm.
The MR cardiac function analysis application is used by physicians to evaluate the structures and function of the heart in the initial screening and subsequent management of coronary disease patients, according to the Redwood City, Calif.-based company.
Ziosoft said its MR cardiac function application provides physicians with the capability to extract left ventricle myocardial contours from Ziosoft's interpolation algorithm. In addition to functional assessment calculations such as ejection fraction, peak filling rate and peak ejection rate, the automatic calculation of myocardial mass also is generated with the Ziosoft application, according to the firm.